Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

AstraZeneca36 enrolled

Overview

This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice. The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cancer

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least one measurable lesion according to RECIST criteria * Histologically or cytologically confirmed NSCLC of adeno histology * Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce Exclusion Criteria: \-

Locations (1)

Research Site

Gueishan Township, Taiwan

Outcomes

Primary Outcomes

PFS of the third-line therapy

Time frame: 9 months

Secondary Outcomes

Overall objective tumor response (complete response [CR] + partial response [PR]) of the third-line therapy by RECIST criteria

Time frame: 9 months